Savara (SVRA) Total Current Liabilities (2010 - 2026)

Savara (SVRA) reported Total Current Liabilities of $15.5 million for Q1 2026, up 30.6% year-over-year from $11.9 million in Q1 2025, and down 23.81% on a QoQ basis from $20.4 million in Q4 2025.

Savara (SVRA) has 17 years of Total Current Liabilities data on file, last reported at $15.5 million in Q1 2026.

  • Quarterly Total Current Liabilities rose 30.6% year-over-year to $15.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.5 million (up 30.6% YoY) and the FY2025 annual result came in at $20.4 million, up 38.52% from the prior year.
  • Total Current Liabilities declined to $15.5 million in Q1 2026 per SVRA's latest filing, from $20.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $20.4 million in Q4 2025 and bottomed at $3.7 million in Q2 2022.
  • The 5-year median for Total Current Liabilities is $11.3 million (2024), against an average of $11.1 million.
  • The widest annual swing landed in 2022, when Total Current Liabilities surged 126.49%; it then tumbled 69.85% in 2023.
  • Tracing SVRA's Total Current Liabilities over 5 years: stood at $5.9 million in 2022, then surged by 80.62% to $10.6 million in 2023, then surged by 38.94% to $14.7 million in 2024, then jumped by 38.52% to $20.4 million in 2025, then dropped by 23.81% to $15.5 million in 2026.
  • Per Business Quant, the three latest SVRA Total Current Liabilities figures stand at $15.5 million (Q1 2026), $20.4 million (Q4 2025), and $16.8 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Current Liabilities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 16.35 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1.70 Mn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 636.40 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 66.94 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 13.42 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 3.88 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 5.11 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.35 Bn
10 Savara 1.30 Bn 1.30 Bn - 15.54 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 15.54 Mn
Dec 31, 2025 20.40 Mn
Sep 30, 2025 16.76 Mn
Jun 30, 2025 13.63 Mn
Mar 31, 2025 11.90 Mn
Dec 31, 2024 14.72 Mn
Sep 30, 2024 12.79 Mn
Jun 30, 2024 11.29 Mn
Mar 31, 2024 9.81 Mn
Dec 31, 2023 10.60 Mn
Sep 30, 2023 8.96 Mn
Jun 30, 2023 5.89 Mn
Mar 31, 2023 4.92 Mn
Dec 31, 2022 5.87 Mn
Sep 30, 2022 5.16 Mn
Jun 30, 2022 3.71 Mn
Mar 31, 2022 16.32 Mn
Dec 31, 2021 14.66 Mn
Sep 30, 2021 10.66 Mn
Jun 30, 2021 5.64 Mn
Mar 31, 2021 7.21 Mn
Dec 31, 2020 8.17 Mn
Sep 30, 2020 7.64 Mn
Jun 30, 2020 6.45 Mn
Mar 31, 2020 7.73 Mn
Dec 31, 2019 10.88 Mn
Sep 30, 2019 8.29 Mn
Jun 30, 2019 9.05 Mn
Mar 31, 2019 8.92 Mn
Dec 31, 2018 7.25 Mn
Sep 30, 2018 11.22 Mn
Jun 30, 2018 7.52 Mn
Mar 31, 2018 5.39 Mn
Dec 31, 2017 6.02 Mn
Sep 30, 2017 6.08 Mn
Jun 30, 2017 8.14 Mn
Mar 31, 2017 6.59 Mn
Dec 31, 2016 3.46 Mn
Sep 30, 2016 20.89 Mn
Jun 30, 2016 25.36 Mn
Mar 31, 2016 22.67 Mn
Dec 31, 2015 23.17 Mn
Sep 30, 2015 13.52 Mn
Jun 30, 2015 10.80 Mn
Mar 31, 2015 9.18 Mn
Dec 31, 2014 8.44 Mn
Sep 30, 2014 7.51 Mn
Jun 30, 2014 5.75 Mn
Mar 31, 2014 6.17 Mn
Dec 31, 2013 4.83 Mn
Sep 30, 2013 3.98 Mn
Jun 30, 2013 3.33 Mn
Mar 31, 2013 3.16 Mn
Dec 31, 2012 2.57 Mn
Sep 30, 2012 2.66 Mn
Jun 30, 2012 2.49 Mn
Mar 31, 2012 1.95 Mn
Dec 31, 2011 2.47 Mn
Sep 30, 2011 3.12 Mn
Jun 30, 2011 2.36 Mn
Dec 31, 2010 1.80 Mn